학술논문

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).
Document Type
Article
Source
Frontiers in Endocrinology; 1/18/2023, Vol. 13, p1-10, 10p
Subject
TYPE 2 diabetes
SEMAGLUTIDE
SYSTOLIC blood pressure
CARDIOVASCULAR diseases risk factors
COHORT analysis
Language
ISSN
16642392
Abstract
Copyright of Frontiers in Endocrinology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)